This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Onglyza

AstraZeneca PLC

Drug Names(s): BMS-477118, OPC-262

Description: Saxagliptin is an inhibitor of di-peptidyl peptidase-IV (DPP-IV), an enzyme that breaks down glucagon-like peptide-1 (GLP-1). GLP-1 binds to receptors on pancreatic beta cells stimulating the release of the hormone insulin. GLP-1 also reduces the secretion of glugacon, a hormone produced by the pancreas that stimulates the liver to convert glycogen to glucose thus increasing blood sugar levels. By delaying the degradation of GLP-1, DPP-IV inhibitors extends the action of insulin while also suppressing the release of glucagon.

A fixed dose combination of saxagliptin and metformin is also approved.

A fixed dose combination of saxagliptin and dapagliflozin, known as SaxaDapa FDC, is also in clinical development.

As of Q1 2014, Onglyze historical revenues also include Kombiglyze XR.

Deal Structure: Revenue splits are BioMedTracker estimates.

In June 2004, OSI acquired a portfolio of medical use patents relating to DPIV from Probiodrug. This portfolio contains a number of patent families comprising issued and pending patents and patent applications with claims relating to the use of DPIV inhibitors for the treatment of diabetes and related indications. OSI also licensed sub-licensable rights to patents and patent applications claiming combinations of DPIV inhibitors with other oral anti-diabetic drugs such as metformin. Its rights to this patent estate provide it with a source of upfront payments, and milestone and royalty revenue through the issuance of non-exclusive licenses to the patent estate. Bristol-Myers Squibb has taken a license to this patent estate.

Otsuka and Bristol-Myers Squibb
In December 2006, Bristol-Myers Squibb and Otsuka Pharmaceutical announced Otsuka had been granted exclusive rights in Japan to develop and commercialize...See full deal structure in Biomedtracker

Partners: Otsuka Holdings Co., Ltd. Bristol-Myers Squibb Company Royalty Pharma AG Kyowa Hakko Kirin Co., Ltd.


Onglyza News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug